Characteristics of the 22 studies included in the metaanalysis: 13 studies that identified prevalence* of SRC within SSc subsets.
| Study | Country (Study Period) | STROBE Checklist, Total = 32 | dcSSc, % | SRC in dcSSc, % | lcSSc, % | SRC in lcSSc, % |
|---|---|---|---|---|---|---|
| Traub, et al9 | USA (1955–1981) | 24 | 100 | 8.82 | NA | NA |
| Montagna, et al 10 | Italy (1965–1994) | 22 | 24.76 | 10.00 | 64.39 | 2.40 |
| Steen and Medsger11 | USA (1972–1995) | 23 | NA | 12.27 | NA | NA |
| DeMarco, et al 1 | USA (1992–1996) | 30 | 100 | 13.43 | 0 | NA |
| Walker, et al 12 | Australia (1983–2000) | 22 | 19.88 | 14.01 | 80.11 | 0 |
| Walker, et al 13 | EUSTAR (2004–2006) | 26 | 36.89 | 4.22 | 57.46 | 1.09 |
| Shand, et al14 | UK (1983–2001) | 31 | 31.76 | 4.63 | 68.23 | 0 |
| Gupta, et al 15 | India (2001–2004) | 25 | 29.88 | 0 | 70.11 | 0 |
| Penn, et al 16 | UK (1990–2005) | 26 | 35.35 | 12.18 | 64.65 | 1.86 |
| Picha, et al 17 | Greece (2008) | 23 | 36.00 | 1.85 | 56.00 | 0 |
| Avouac, et al 18 | Italy (1966–2009) | 22 | 30.05 | 4.85 | 69.96 | 0 |
| Joven, et al 19 | Spain (1980–2006) | 24 | 30.39 | 3.23 | 59.31 | 1.65 |
| Guillevin, et al20 | France | 28 | 43.05 | 34.98 | 56.94 | 4.41 |
↵* Prevalence is ever SRC. SRC: scleroderma renal crisis; SSc: systemic sclerosis; STROBE: Strengthening the Reporting of Observational Studies in Epidemiology; dcSSc: diffuse cutaneous SSc; lcSSc: limited cutaneous SSc; NA: not applicable; EUSTAR: European League Against Rheumatism Scleroderma Trial and Research Group.